Last reviewed 2026-04-23 · How we verify

Begrivac®

Begrivac is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.

Begrivac is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for Melanoma (adjuvant setting, in combination with checkpoint inhibitors).

At a glance

Mechanism of action

Begrivac is an individualized neoantigen-based therapeutic vaccine that is engineered based on each patient's unique tumor mutations. It works by training the patient's immune system to identify and eliminate cancer cells that express these personalized neoantigens, thereby enhancing anti-tumor immunity and potentially preventing recurrence.

Approved indications

• Melanoma (adjuvant setting, in combination with checkpoint inhibitors)

Common side effects

• Injection site reactions
• Fatigue
• Fever
• Myalgia

Key clinical trials

• Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus (PHASE3)
• Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection (PHASE3)
• Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011 (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Begrivac® CI brief — competitive landscape report
• Begrivac® updates RSS · CI watch RSS
• Chiltern Pesquisa Clinica Ltda portfolio CI